CRBN

Across TCGA pan-cancer cohorts, CRBN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CRBN data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRBN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRBN expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where CRBN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.608	0.319	.002	53	view →
CCRCC	DFS	Tertile	III,IV	0.861	0.535	.023	25	view →
UCEC	OS	Median	III,IV	0.300	0.926	.009	20	view →
COAD	DFS	Tertile	All	1.000	0.864	.045	12	view →
LUAD	DFS	Quartile	III,IV	0.411	0.852	.016	10	view →
GBM	DFS	Tertile	All	0.276	0.517	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CRBN–PDAC (DFS)

Open the PDAC breakdown →